Centron Bio
Centron Bio is a cutting-edge biotechnology company pioneering next-generation genetic medicines for Central Nervous System (CNS) diseases. Centron Bio leverages world-class research and deep expertise in RNA-based therapeutics, peptide delivery, precision medicine, and translational neuroscience to develop breakthrough treatments for patients with high unmet medical needs.
-
James Tran, PhD
CEO
-
Jiah Pearson-Leary
Head of Corporate Development
-
Rick Pierce
Chair-elect
Interactome Biotherapeutics
Interactome is advancing its native nano platform, a next-generation, multi-targeted Secretome containing hundreds of biologically active proteins and other factors crucial for cellular regeneration, the modulation of inflammation, cell recovery and turnover. This novel platform could hold significant clinical potential across a range of important underserved conditions in neurology and cardiology.
Paralog Therapeutics
Paralog Therapeutics is a pre-clinical stage precision medicine company focused on the development of anti-cancer therapies. Paralog Therapeutics’ mission is to identify and leverage synthetic vulnerabilities in cancers that carry specific gene alterations.
-
Tiziana Parisi, PhD
CEO, CSO & Co-founder
-
Steen Hansen, PhD, MD
President & Academic Co-founder
State 4 Therapeutics
State 4 Therapeutics is developing oral small molecule therapies that synergize with nutrient-stimulated hormones for the treatment of obesity and metabolic diseases.
-
Dick Kibbey, MD, PhD
Scientific Founder
-
Matt Merrins, PhD
Scientific Founder
-
Ania Jastreboff, MD, PhD
Founder, Clinical Scientific Advisor
-
Robert Williams, PhD
Lead Operator
TMAB Therapeutics
TMAB Therapeutics is developing first-in-class multi-specific antibodies designed to enhance immune activation while inhibiting angiogenesis within the solid tumor microenvironment. By simultaneously targeting CD5L and EGLF6, TMAB Therapeutics aims to overcome adaptive resistance to anti-VEGF and anti-PD1 therapies, offering a novel treatment approach for non-small cell lung cancer, microsatellite-stable colorectal cancer, and high-grade serous epithelial…
-
Tinashe Chandauka, MD, PhD
Co-founder & CEO
-
Josh Sharan, DO
Co-founder & COO
D2B3
Over 98% of all drugs struggle to cross the Blood-Brain Barrier (BBB), hindering their usability against CNS diseases. D2B3’s breakthrough is a patented human monoclonal antibody (Mab), that transiently and highly specifically opens the BBB, achieving high drug penetration to the brain. The lead asset D2B3-01 has shown exceptional performance in in vivo proof of…
-
Manuel Mohr, PhD
Co-founder, Founding CEO
-
Anne Eichmann, PhD
Co-founder, Chief Scientific Advisor
-
Kevin Boyé, PhD
Co-founder, Lead Scientist/Advisor
Harbor Biomedicines
Harbor Biomedicines, a Harvard/Wyss Institute spinoff, is pioneering a safe and efficient gene insertion technology to provide curative treatments for rare genetic and common disorders. By engineering compact, simple yet potent enzymes — recombinases — Harbor Biomedicines can efficiently and precisely integrate large DNA cargos into genomic safe harbors for robust and durable therapeutic gene…
-
George Church, PhD
SAB Chair
-
Tina Lebar, PhD
SAB Member
Lybra Bio
Lybra Bio is reshaping the treatment landscape of Autoimmune Skin Diseases. They are developing innovative therapeutics platforms aiming to restore the skin’s immune equilibrium in patients suffering from Autoimmune Skin Diseases. Lybra Bio’s first platform combines clinically validated cytokines loaded into an advanced microneedle patch for superior efficacy and patient compliance while bypassing systemic side…
-
Núria Puigmal, PhD
Founder
-
Jamil R. Azzi, PhD, MD
Academic Co-founder
-
Natalie Artzi, PhD
Academic Co-founder
Modulate Bio
Modulate Bio is advancing a new generation of fine-tuned neuro-medicines to treat a range of neurological disorders. Modulate Bio’s platform enables them to precisely treat neurological disorders like Essential Tremor, epilepsy and anxiety by restoring healthy brain receptor function, without overactivating. Modulate Bio has achieved in vivo proof-of-concept in mice and are close to identifying…
-
Dr. Dario Doller, PhD
CSO
-
Kevin Hodgetts, PhD
SAB Chair
RedPoint Oncology
RedPoint Oncology is a targeted precision oncology company, leveraging next-generation antibody-drug conjugates to develop best-in-class therapies for lethal solid tumors with no cure.
-
Mengdie Wang, PhD
Co-founder, CEO
-
Arthur Mercurio, PhD
Co-founder/Advisor
DoriNano
DoriNano aims to harness the potential of DNA origami technology to develop safe, effective, and low-cost combination nanomedicines that have precise cellular targeting with minimal effective doses of cargo for serious diseases. The company’s platform sets out to solve the past limitations of nanoparticles for delivering therapeutic cargo, offering unique advantages such as programmable size…
-
Yang Claire Zeng, MD, PhD
Founder & CEO
Hestia Therapeutics
Hestia Therapeutics, lending its name from the Greek goddess of the hearth, aims to bring inflammatory cells into the tumor microenvironment to unleash anti-tumor effects from within. Currently, more than 70% of cancer patients have tumors that are shielded from the immune cells directed by checkpoint inhibitors to kill cancer cells, leading to disease progression.…